Streetbeat News

Stock Prices

PACS

A class action lawsuit has been filed against PACS Group, Inc. (NYSE:PACS) with a deadline of January 13, 2025, for investors to join. The lawsuit is related to potential recovery under federal securities laws.

Portfolio Pulse from

November 15, 2024 | 12:00 am

HHS

Harte-Hanks (HHS) reported Q3 earnings of $0.13 per share, surpassing the Zacks Consensus Estimate of $0.10 per share, and showing growth from $0.08 per share a year ago.

Portfolio Pulse from

November 15, 2024 | 12:00 am

GOOG

Alphabet's stock experienced a decline on Thursday due to unspecified reasons.

Portfolio Pulse from

November 14, 2024 | 11:45 pm

CVS

Investment firms Glenview, Sachem Head, and Third Point have increased their stakes in CVS Health during the third quarter, indicating potential upcoming changes at the company.

Portfolio Pulse from

November 14, 2024 | 11:45 pm

CUE

Cue Biopharma, Inc. (CUE) reported a Q3 loss of $0.17 per share, which was better than the Zacks Consensus Estimate of a $0.20 loss. This is an improvement from the $0.24 loss per share reported a year ago.

Portfolio Pulse from

November 14, 2024 | 11:45 pm

SMCI

Super Micro Computer's stock has dropped approximately 85% from its peak, raising questions about whether it is now a good buying opportunity despite its high-risk status.

Portfolio Pulse from

November 14, 2024 | 11:45 pm

SPOT

Spotify Technology (SPOT) shares have surged over 15% following the release of its Q3 earnings, indicating positive investor sentiment towards its growth narrative.

Portfolio Pulse from

November 14, 2024 | 11:45 pm

ACHC

Faruqi & Faruqi, LLP is investigating potential claims against Acadia Healthcare (NASDAQ: ACHC) and reminds investors of the December 16, 2024 deadline to seek the role of lead plaintiff in a federal securities class action. Investors who suffered losses exceeding $100,000 between February 28, 2020, and September 26, 2024, are encouraged to contact the firm.

Portfolio Pulse from

November 14, 2024 | 11:45 pm

DARE

Dare Bioscience, Inc. (DARE) reported a Q3 loss of $0.55 per share, which was better than the Zacks Consensus Estimate of a $0.60 loss. However, the company lagged in revenue estimates.

Portfolio Pulse from

November 14, 2024 | 11:30 pm

NFE

Levi & Korsinsky has notified investors of New Fortress Energy Inc. (NASDAQ:NFE) about a class action lawsuit and an upcoming deadline for potential recovery under federal securities laws.

Portfolio Pulse from

November 14, 2024 | 11:30 pm